Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
By
Wayne Kuznar
Leukemia
,
Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—The combination of duvelisib (Copiktra) plus venetoclax (Venclexta) is a promising all-oral regimen for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Read Article
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma
By
Phoebe Starr
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—The investigational dual-targeted CD38 chimeric antigen receptor (CAR) T-cell therapy achieved an objective response in more than 90% of patients with relapsed or refractory multiple myeloma who had received ≥3 previous therapies and whose disease had spread outside of the bone marrow. Furthermore, the therapy cleared extramedullary lesions in almost all patients with these lesions, according to results presented at ASH 2019.
Read Article
Surgery for Cholangiocarcinoma
Cholangiocarcinoma
,
Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
At the First Annual Cholangiocarcinoma Summit, presenters discussed recent advances in the management of patients with cholangiocarcinoma (CCA).
Read Article
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
By
Yvette Florio Lane
FDA Approvals, News & Updates
,
In the News
,
Lung Cancer
,
Personalized Medicine
,
Thyroid Cancer
Web Exclusives
On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced
RET
fusion-positive non–small-cell lung cancer,
RET
-mutant medullary thyroid cancer, and
RET
fusion-positive thyroid cancer.
Read Article
Nivolumab plus Ipilimumab Combination Improves Survival in Patients with Metastatic NSCLC
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
December 2019, Vol 10, No 6
Barcelona, Spain—The immunotherapy combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved overall survival (OS) compared with chemotherapy as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC) and PD-L1 expression ≥1%, according to results of CheckMate 227.
Read Article
Osimertinib Superior TKI as First-Line Treatment of Advanced NSCLC with EGFR Mutation
By
Phoebe Starr
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
December 2019, Vol 10, No 6
Barcelona, Spain—Osimertinib (Tagrisso), a third-generation EGFR tyrosine kinase inhibitor (TKI), extended overall survival (OS) compared with older TKI EGFR inhibitors, including gefitinib (Iressa) or erlotinib (Tarceva), as first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) and
EGFR
mutation in the phase 3 clinical trial called FLAURA.
Read Article
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials
By
Chase Doyle
Clinical Trials
,
Personalized Medicine
October 2019, Vol 10, No 5
San Diego, CA—New research sponsored by the National Cancer Institute highlights the uphill battle faced by patients with limited financial resources even in clinical trials. According to data presented at the 2019 ASCO Quality Care Symposium, patients with Medicaid or with no insurance had significantly worse overall survival in positive clinical trials compared with privately insured patients.
Read Article
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
By
Phoebe Starr
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
October 2019, Vol 10, No 5
Chicago, IL—Treatment with the immune checkpoint inhibitor pembrolizumab (Keytruda) dramatically improved 5-year survival for patients with advanced non–small-cell lung cancer (NSCLC) compared with expected survival in the preimmunotherapy era, according to the 5-year follow-up data from the phase 1b KEYNOTE-001 clinical trial. The study was presented at ASCO 2019 and was published simultaneously in the
Journal of Clinical Oncology
.
Read Article
Page 2 of 35
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma